SCHEMBL30795486

SCHEMBL30795486

CC(C)(C)CC(=O)Nc1ccc(NCc2ccc(Cl)s2)cc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.44
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
KCNQ3 O43525 2/20 0.39
KCNQ2 O43526 2/20 0.39
KCNQ4 P56696 1/20 0.39
KCNQ5 Q9NR82 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
F2 P00734 5/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3112428 1.00 FFAR1 (0.44) FFAR1HDAC1HDAC2KCNQ3KCNQ2
SCHEMBL30795826 0.89 FFAR1 (0.46) FFAR1RAB9AADORA2AADORA1F2
SCHEMBL2070719 0.89 FFAR1 (0.46) FFAR1RAB9AADORA2AADORA1F2
SCHEMBL4998440 0.83 FFAR1 (0.41) FFAR1RAB9ANPC1HTTSMN1; SMN2
SCHEMBL3101974 0.80 KCNQ2 (0.62) FFAR1HDAC1HDAC2KCNQ3KCNQ2
SCHEMBL30795181 0.80 KCNQ2 (0.62) FFAR1HDAC1HDAC2KCNQ3KCNQ2
SCHEMBL3090964 0.80 HDAC1 (0.53) FFAR1HDAC1HDAC2KCNQ3KCNQ2
SCHEMBL30794887 0.80 HDAC1 (0.53) FFAR1HDAC1HDAC2KCNQ3KCNQ2
SCHEMBL5096446 0.80 HDAC1 (0.40) HDAC1HDAC2KCNQ3KCNQ2RAB9A
SCHEMBL2070657 0.75 FFAR1 (0.47) FFAR1F2HTTMAPTUTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed